0001209191-18-033239.txt : 20180525 0001209191-18-033239.hdr.sgml : 20180525 20180524202903 ACCESSION NUMBER: 0001209191-18-033239 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180525 DATE AS OF CHANGE: 20180524 EFFECTIVENESS DATE: 20180525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acasti Pharma Inc. CENTRAL INDEX KEY: 0001444192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-313258 FILM NUMBER: 18859450 BUSINESS ADDRESS: STREET 1: 545 PROMENADE DU CENTROPOLIS, SUITE 100 CITY: LAVAL STATE: A8 ZIP: H7T 0A3 BUSINESS PHONE: 450-686-4555 MAIL ADDRESS: STREET 1: 545 PROMENADE DU CENTROPOLIS, SUITE 100 CITY: LAVAL STATE: A8 ZIP: H7T 0A3 D 1 primary_doc.xml X0708 D LIVE 0001444192 Acasti Pharma Inc. 545 Promende du Centropolis Suite 100 Laval A8 QUEBEC, CANADA H7T 0A3 (450) 686-4555 QUEBEC, CANADA None None Corporation true Janelle D'Alvise 545 Promenade du Centropolis Suite 100 Laval A8 QUEBEC, CANADA H7T 0A3 Executive Officer Director Linda P. O'Keefe 545 Promenade du Centropolis Suite 100 Laval A8 QUEBEC, CANADA H7T 0A3 Executive Officer Roderick N. Carter 545 Promenade du Centropolis Suite 100 Laval A8 QUEBEC, CANADA H7T 0A3 Director Jean-Marie (John) Canan 545 Promenade du Centropolis Suite 100 Laval A8 QUEBEC, CANADA H7T 0A3 Director Donald Olds 545 Promenade du Centropolis Suite 100 Laval A8 QUEBEC, CANADA H7T 0A3 Director Biotechnology Decline to Disclose 06b false 2018-05-09 false true true true true Each unit consists of one common share and one common share purchase warrant exercisable at any time prior to May 9, 2023 at an exercise price of CDN$1.31 per common share. false 0 Mackie Research USA Inc. 39670 Mackie Research Capital Corporation None 199 Bay Street, Suite 4500 Commerce Court West, Box 368 Toronto A6 ONTARIO, CANADA M5L 1G2 NY NEW YORK 837546 372637 464909 The additional U.S.$464,909.38 may be received upon the exercise of warrants sold in the U.S. The U.S. dollar amounts are based on the Bank of Canada noon rate of exchange reported on May 9, 2018, which was CDN$1.00=U.S.$1.2856. false 1 26084 0 0 false Acasti Pharma Inc. /s/ Linda P. O'Keefe Linda P. O'Keefe Chief Financial Officer 2018-05-24